Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/132055
|
| Title: | 藥品法規的差異性對台、美原料藥產業的影響
The Impacts of Regulations on Taiwan and United States Active Pharmaceutical Ingredient Industry |
| Authors: | 吳品慧
Wu, Pin-Hui |
| Contributors: | 陳桂恒
吳品慧
Wu, Pin-Hui |
| Keywords: | 製藥產業
原料藥
藥品優良製造規範
食品藥物管理局
Pharmaceutical Industry
Active Pharmaceutical Ingredient (API)
Drug Master File (DMF)
Good Manufacture Practice (GMP)
Food and Drug Administration (FDA)
Common Technical Document (CTD) |
| Date: | 2013 |
| Issue Date: | 2020-10-05 15:15:09 (UTC+8) |
| Abstract: | 藥品是確保人類健康延續生命不可或缺的物品。藥品的服用會直接影響人體，因此藥品的製造需要完善的設計，縝密的監控，及高度的法規來控制其品質並確保其安全性及有效性。藥品除了受每個國家個別的法規管理之外，由於市場全球化，國際間也在推動管理標準及相互認證，以避免研究資料及審查時間的重複與浪費，也進以確保人民可以快速的取得優良品質的救命藥品。因此，法規的管理及其所帶來對產業的影響即是本論文所探討之重點。
相較於一般較熟悉的藥品製劑產業，原料藥雖僅為製藥產業的中游原料且市值也相對小，但由於是藥品中之有效成份，其品質及其物理性及化學特性卻是影響藥品的關鍵因素。近年來台灣原料藥廠因品質好且技術層次較中國及印度高，而價格又比日本等先進國家便宜，因此台灣原料藥廠紛紛站上國際舞台，供貨給歐、美等高法規限制市場，擴大了其市場及產能。而國內製藥產業的主力-學名藥，除了供給國內需求之外，也在主管關機台灣食品藥物管理局近年來推動並實施了許多與國際接軌的法規後，紛紛嘗試出口藥品至東南亞國家以外之歐、美市場。但國內學名藥廠所使用之原料藥大部分為國外進口，其中又以中國及印度為主，雖近年來國內並沒有發生因原料藥品質問題所產生重大事件，但病人與醫生對於國內學名藥之療效無法與原廠藥相同的聲音一直存在。鑿於藥品是使用在病人身上的最終產品，任何一個好品質的藥品，除了製造過程應嚴謹處理外，都應從源頭管理，即是其主成分:原料藥。原料藥非最終消費產品，原料藥大部分是化學合成，其生產廠是化學工廠的延伸，因此法規的管理與藥品也略有不同。一般化學品並准也不能直接使用在人體，不需要藥品的法規來管理，而同屬化學品之原料藥 因其對人體生命的重要性及其嚴重性，如何適當管理是一個很嚴肅卻較少人研究的課題。台灣現行原料藥的法規尚未像製劑產品一樣的與國際同步，且對進口原料藥及國內產製之原料藥的管理規範亦不盡相同。 因此本論文將探討國際上針對原料藥品質控管之規範，比較美國及台灣原料藥上市規範，並加入台灣產業實務上操作之狀況與意見，綜合考量後提出針對原料藥管理台灣法規面的相關建議。
近年來各個跨國性的大藥廠紛紛將原料藥委外製造或對外購買，加上又一波的專利藥品即將到期，台灣原料藥廠可否把握此機會再創另一高峰令人期待。同時，雖然台灣製藥產業大多以生產學名藥為主，目前尚未有從新藥開發並經過臨床試驗到審核上市的案子，但由於台灣的研發能力高，且已有幾個由台灣廠商研發並經過初期臨床試驗後就技轉給國際大藥廠的案例。因此本論文也將探討我國針對新成分原料藥之法規是否能有助於原料藥產業及促進新藥之研發上市。
Drug product is indispensable to maintain health and prolong human life; since drug consumption directly affects human body, to control the quality of a drug product and ensure its safety and effectiveness, the manufacture of drug product needs to be well designed, monitored and regulated strictly by laws. In addition to being controlled and regulated by individual regulatory system in every countries, as the market is globalized, the activity of harmonizing the regulation requirements between each health authorities and setting the international standards are also been working on in order to avoid wasting of resources of industries on repeating work of preparing the similar drug dossiers on the same product for launching in different countries; it is also to speed up the review process for drug approval so that patient would have quicker access to high quality of drug products. Therefore, the main focus of this paper is to discuss the regulation of Active Pharmaceutical Ingredient (also called drug substance) and its impacts to the industry.
Although comparing to the drug product/medicine industry, which people are more familiar with, API is only one of the components of drug product with smaller market value, yet as API is the main active ingredient of the drug product, its physical and chemical properties are the key factors affecting the drug product, its formulation and dosage form. In recent years, Taiwan API manufacturers become well-known on the international market due to its high quality in special nichec, and advanced technology with fairly reasonable price. Local API mnufacturers started exporting APIs to regulated markets such as the United States and Europe. As for local drug product manufacturers, which are mainly generic manufacturers/companies, while meeting the local needs, they also strive to export drug products not only to South East Asia but also slowly to the US and EU markets. However, most APIs which local generic companies use are imported from China and India, which the regulated level is not as high. Although there has not been any major quality issue with API, yet there are noises from the doctor and patient that the efficacy of generic drug can hardly deem to be the same as the originator`s brand name drug. As drug product is the end product which is consumed by patients, any “good quality” drug product should not only be well controlled with strict monitoring of manufacturing process, but starting from the beginning - API sourcing. Yet, the regulations of API should be different from drug product as API is not the end product and it is mostly chemically synthesized. Normally chemicals are not allowed to be used directly on human bodies and therefore do not need to be regulated; however, as API is a chemical compound, which would have direct and serious effect on human, how to management and regulat API properly is a less discussed but serious topic. The current regulations of drug substance in Taiwan have not been as “internationalized” like drug product, and there are also different policies for imported API and locally produced API. Therefore, this paper will introduce the current internal standard on controlling the API quality, and will compare the regulation systems of API registration in the US and Taiwan with practical practice going on in the industry. After the comprehensive introduction and evaluation, comments and suggestions will be proposed.
In recent years, many multinational drug product companies tend to have contract manufacturers to manufacture or outsource the needed API; in addition, many API compound patents will be expired soon, it is exciting to see if Taiwan API manufacturers can catch thess opportunities, expand their business and bring it to the next level. Although Taiwan pharmaceutical industries are more specialized in generic product, and there has not been any case of new drug development from drug discovery, clinical study, to product launch. However, as there are successful cases of licensing out brand new drug candidates to multinational companies after preliminary clinical study or even early clinical trial study, with strong search and development capability in Taiwan, therefore, the topic of how the brand new drug substance are regulated are also discussed to see if the current regulation can help the growth of API industry and enhance research and development of new drug products. |
| Reference: | 一、中文文獻
(一)書籍
王大維（2005），全球仿效藥發展現況與未來切入策略探討，新竹縣:工業技術研
究院產業經濟與資訊服務中心。
朱延智 (2010)，高科技產業分析，台北市：五南圖書。
尤格．布雷希（2013），發明疾病的人：現代醫療產業如何賣掉我們的健康？，
台北市：左岸文化。
邱欣怡譯，Howland, R., Mycek, M.（2006），最新圖解藥理學，台北市：合記圖書。
巫文玲（2012），全球及五國產業各領域現況-原料藥產業，新北市：財團法人生
物技術開發中心。
范佐勳（2001），台灣藥學史，台北市：財團法人鄭氏藥學文教基金會。
張明富（2005），特定標的之新藥開發，台北市：醫藥基因生物技術教學資源中
心。
陳君愷（1992），日治時期台灣醫生社會地位之研究，台北：師範大學歷史研究所。
湯谷清、羅淑慧、廖美智、賴瓊雅、巫文玲、許毓真、黃詩芳、陳正揚、黃雅婷
（2012），醫藥產業年鑑，新北市：財團法人生物技術開發中心。
黃耀能（1998），日據時期藥劑師與藥品管理，政事志戶政篇、衛生篇，
南投市：南投縣政府。
瑪西亞．安卓（2012），藥廠黑幕：製藥公司如何掏空以的錢包和健康?，台北市：
商周出版社。
羅敏菁（2012），生技投資聖經，台北市：旗標。
(二)期刊
郭珮筑（2010），PIC/S促使製藥業大洗牌？生技與醫療器材報導月刊，130。
陳惠芳（2010），國內實施PIC/S GMP國際標準情形及對於用藥品質之影響，台
灣醫界，53，22。
陳惠玲、王澤民、陳志維、陳映樺、黃琴喨、陳惠芳（2011），西藥製劑廠使用
自用原料之現況調查，食品藥物研究年報2，40-44。
黃慧嫺（2009），專利連結-藥品研發與競爭之阻力或助力?談藥品查驗登記程序
與專利狀態連結之發展(上)，科技法律透析，21:3，32-48。
廖美智（2013），Supergenerics將於全球藥品市場崛起，醫藥生技產業透析，49，1。
羅昌發（1997），WTO架構下智慧財產與競爭法之關係，行政院公平交易委員會
1997年合作研究計畫，頁39-49。
(三)論文
江秀彥（2006），台灣藥業發展中國家角色之分析，國立中山大學政治學研究所
在職專班碩士論文。
胡宏達（2009），藥品智慧財產於藥品查驗登記程序中之保護，東吳大學法律學
系碩士在職專班專業法律組碩士論文。
鄭耀誠（2009），論藥品研發、上市許可之規範與相關智慧財產權之保護-專利連
結、資料專屬與專利權之探討，私立輔仁大學財經法律學系碩士班。
(四)研討會資料
李榮安（2010），美國藥物主檔案(DMF)準則簡介，原料藥DMF審查現況說明會。
陳瑩如（2013），原料藥主檔案(含經實及一般送審)與國產原料藥查驗登記文件資料之準備須知，102年度原料藥主檔案與原料藥查驗登記審查之法規科學說明會。
張琳巧（2013），應用通用技術文件格式於學名要查驗登記化學製造管制資料送 件說明，102年度應用通用技術文件格式於學名要查驗登記送件暨國產藥品許可證展延變更說明會。
張簡雅青（2012），製劑廠使用自用原料藥品質管理之分享，原料藥DMF管理制
度實施方法研討會。
連恆榮（2012），藥品查驗登記電子送件及通用技術文件格式推動與展望，藥品
查驗登記電子送件暨通用技術文件格式業界推廣說明會。
鄒玫君(2011)，台灣學名藥上市許可程序與藥品品質管理，台德學名藥法律制度
研討會。
顧曼芹（2013），US FDA ANDA Regulation Update，美國藥品市場策略研討會。
二、外文文獻
(一) Books
Immel, B. K. (2001). A Brief History of the GMPs for Pharmaceuticals.
Pharmaceutical Technology.
Porter, R. J. (2002). Chapter 3 - Clinical Development of Antiepileptic drugs: Industry Perspective. Antiepileptic Drug.
Spilker, B. (2009). Guide to Drug Development: A Comprehensive Review and Assessment. Lippincott Williams￡Wilkins.
(二) Articles
Fabian, A.C. (1999). Principles for Effective Regulatory Active Pharmaceutical
Ingredient Policy. Drug Information Journal, 22, 747-753.
Velagaleti, R., Burns, P. K., & Gill, M. (2003). Analytical Support for Drug
Manufacturing in the United States – From Active Pharmaceutical Ingredient Synthesis to Drug Product Shelf Life. Drug Information Journal, 37, 407
Molzon, J. A.; Giaquinto, A.; Lindstrom, L.; Tominaga, T.; Ward, M.; Doerr, P.; Hunt,
L.; & Rago, L. (2011). The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health. Clinical Pharmacology & Therapeutics, 89(4), 503-512.
三、網路資源
台灣藥物法規資訊網：http://regulation.cde.org.tw/
行政院衛生署食品藥物管理局：http://www.fda.gov.tw/TC/index.aspx
全國法規資料庫：http://law.moj.gov.tw/Index.aspx
食品藥物消費者知識服務網：
http://consumer.fda.gov.tw/Pages/Detail.aspx?nodeID=128&pid=5374
ICH網站：http://www.ich.org/about/organisation-of-ich/steering.html
PIC/S網站：http://www.picscheme.org/
US FDA網站：http://www.fda.gov/default.htm
USP網站：http://www.usp.org/about-usp
WHO網站：
http://www.who.int/biologicals/vaccines/good_manufacturing_practice/en/index.html |
| Description: | 碩士
國立政治大學
智慧財產研究所
96361017 |
| Source URI: | http://thesis.lib.nccu.edu.tw/record/#G0096361017 |
| Data Type: | thesis |
| DOI: | 10.6814/NCCU202001745 |
| Appears in Collections: | [智慧財產研究所] 學位論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 101701.pdf | | 4606Kb | Adobe PDF2 | 574 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
